173 related articles for article (PubMed ID: 18801884)
1. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
2. Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.
Thiery-Vuillemin A; Montange D; Kalbacher E; Maurina T; Nguyen T; Royer B; Bouchet S; Bazan F; Curtit E; Pivot X
Ann Oncol; 2011 Sep; 22(9):2152-2154. PubMed ID: 21878429
[No Abstract] [Full Text] [Related]
3. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Mizuno T; Terada T; Kamba T; Fukudo M; Katsura T; Nakamura E; Ogawa O; Inui K
Ann Oncol; 2010 Jun; 21(6):1382-1383. PubMed ID: 20348146
[No Abstract] [Full Text] [Related]
4. Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
J Med Case Rep; 2017 Feb; 11(1):28. PubMed ID: 28143610
[TBL] [Abstract][Full Text] [Related]
5. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
Ravaud A; Bello CL
Anticancer Drugs; 2011 Jun; 22(5):377-83. PubMed ID: 21394020
[TBL] [Abstract][Full Text] [Related]
6. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
[TBL] [Abstract][Full Text] [Related]
7. Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.
Bertolaso P; Gross-Goupil M; Molimard M; Cochin V; Ravaud A; Daste A
Clin Genitourin Cancer; 2017 Oct; 15(5):e885-e887. PubMed ID: 28552572
[No Abstract] [Full Text] [Related]
8. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
9. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
10. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
11. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Garfield DH; Hercbergs A; Davis PJ
J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
[No Abstract] [Full Text] [Related]
12. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
13. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Lankheet NA; Blank CU; Mallo H; Adriaansz S; Rosing H; Schellens JH; Huitema AD; Beijnen JH
J Anal Toxicol; 2011 Oct; 35(8):558-65. PubMed ID: 22004675
[TBL] [Abstract][Full Text] [Related]
14. Remission of diabetes while on sunitinib treatment for renal cell carcinoma.
Templeton A; Brändle M; Cerny T; Gillessen S
Ann Oncol; 2008 Apr; 19(4):824-5. PubMed ID: 18326519
[No Abstract] [Full Text] [Related]
15. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
16. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib-aggravated hypertension.
Rivera F; Benounna M; Sánchez de la Nieta MD
J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
[No Abstract] [Full Text] [Related]
19. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
[TBL] [Abstract][Full Text] [Related]
20. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
